摘要
目的 :应用 PHMA0 2单抗对 AL 患者 Pgp的表达进行检测 ,并对该单抗的特异性、检测结果与临床符合率以及预后的准确性进行评估。方法 :应用间接免疫荧光法、RT- PCR法检测了 10 1例 AL 患者 ;用医学统计软件分析数据。结果 :难治和复发组的 MDR+表达率 (5 2 .9% )明显高于初诊组 (19.2 % ) (P<0 .0 1) ;难治和复发组的 CR率 (2 1.4% )明显低于初诊组 (6 8.7% ) (P<0 .0 1) ;初诊组中 MDR+表达患者的 CR率 (2 1.4% )明显低于MDR- 患者 (81.1% ) (P<0 .0 1) ;PHMA0 2单抗的检测结果与国外同型单抗 JSB- 1的平行检测结果呈正的直线相关 (P<0 .0 5 ) ,与 RT- PCR的检测结果具有相关性 (P<0 .0 1)。结论 :PHMA0 2单抗的检测结果与临床有较好的符合率 ,可在临床应用。 MDR- 表达的初诊患者预后较好 ,CR率较高 ;MDR+ 表达的复发和难治的 AL患者 ,预后差 ,CR率极低 ,这两组患者的 Pgp表达具有一定的预后价值。
Objective:The expression of Pgp was detected in AL using PHMA02 antibody,evaluate for the specificity of the antibody,and investigate the accuration of predicting chemotherapy response and prognosis.Methods:Indirect immunofluorescence assay and RT PCR were used to analyze the expression of mdr gene in 101 AL patients,the data were analyzed by statistics.Results:The expression rate of MDR + in refractory relapsed group was significantly higher than in untreated group( P <0.01).The results of detection with PHMA02 antibody paralleled that of JSB 1 and RT PCR( P <0.05).Conclusion:The results of detection with PHMA02 antibody accorded well with drug resistance in AL in clinic and showed that the antibody can be used in clinic.The MDR - patients in untreated group had a good prognosis and the CR rate was higher.On the contrary,the MDR + patients in refractory relapsed group had a poor prognosis,so expression of Pgp in these two groups is a valuable factor for predicting the response and prognosis of chemotherapy.
出处
《白血病》
2000年第6期325-327,共3页
基金
国家九五攻关课题基金!资助项目! (96 -90 6 -0 1-2 3)
